Howard Bailey

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity
    Sarah M Kreul
    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA
    Cancer Prev Res (Phila) 5:1368-74. 2012
  2. ncbi A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients
    Edward Messing
    University of Rochester Medical Center, Rochester, New York, USA
    Cancer Prev Res (Phila) 5:621-30. 2012
  3. ncbi The Wisconsin Network for Health Research (WiNHR): a statewide, collaborative, multi-disciplinary, research group
    Howard Bailey
    University of Wisconsin School of Medicine and Public Health, Madison 53792, USA
    WMJ 108:453-8. 2009
  4. ncbi Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy
    Sherry Morgan-Meadows
    University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA
    Invest New Drugs 20:377-82. 2002
  5. ncbi Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer
    Sherry Morgan Meadows
    Department of Medicine, Division of Medical Oncology, The University of Wisconsin, Madison, WI, USA
    Int J Gastrointest Cancer 32:125-8. 2002
  6. ncbi Phase I trial of perillyl alcohol administered four times daily continuously
    Sherry Morgan-Meadows
    University of Wisconsin Comprehensive Cancer Center, 600 Highland Ave K4 601, Madison, Wisconsin 53792, USA
    Cancer Chemother Pharmacol 52:361-6. 2003
  7. ncbi A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma
    Sherry Morgan-Meadows
    University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792, USA
    Oncology 69:130-4. 2005
  8. ncbi A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors
    William Schelman
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K4 530 CSC, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 62:727-33. 2008
  9. ncbi The differential diagnosis of pulmonary blastomycosis using case vignettes: a Wisconsin Network for Health Research (WiNHR) study
    Dennis J Baumgardner
    Department of Family Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee, USA
    WMJ 110:68-73. 2011

Collaborators

  • GEORGE A WILDING
  • Jordan D Berlin
  • Jonathan L Temte
  • Dennis J Baumgardner
  • Sarita Dubey
  • S H Yale
  • J M Kolesar
  • D L DeMets
  • Sherry Morgan-Meadows
  • Kyungmann Kim
  • James P Thomas
  • Edward Messing
  • Sarah M Kreul
  • Dona Alberti
  • Daniel Mulkerin
  • William Schelman
  • Jennifer Volkman
  • Chris Feierabend
  • Sherry Morgan Meadows
  • Gary S Wood
  • Margaret House
  • Abbey Borich
  • Thomas Havighurst
  • Linda Harris
  • Howard Parnes
  • Daniel R Saltzstein
  • Marcia A Wheeler
  • Robert H Getzenberg
  • AJIT VERMA
  • Raymond Hohl
  • Stephen Snow
  • Mitchell Efros
  • J Erik Busby
  • Joseph Tangrea
  • Tom Havighurst
  • Jason R Gee
  • Anthony Disant'agnese
  • Jay M Young
  • Adrienne Faerber
  • Eneida A Mendonca
  • Kyle Holen
  • Heidi Brandon
  • Kate Oliver
  • Jens Eickhoff
  • Thomas Saphner
  • Alcee Jumonville
  • Thomas McFarland
  • Richard Hansen
  • Harish Ahuja
  • Rebecca Marnocha
  • Kimberly Binger
  • Sandra Black
  • Michael Gould
  • Kendra Tutsch
  • Rhoda Arzoomanin
  • Shawna Ellingen
  • Marcia Pomplun
  • Rebecca Marrocha
  • Kim Binger
  • Deb Warren
  • Rhoda Z Arzoomanian

Detail Information

Publications9

  1. ncbi A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity
    Sarah M Kreul
    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA
    Cancer Prev Res (Phila) 5:1368-74. 2012
    ..107, P = 0.43) are listed. Follow-up data revealed a persistent but insignificant reduction in new NMSCs occurring in DFMO subjects without evidence of latent or cumulative toxicity relative to placebo subjects...
  2. ncbi A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients
    Edward Messing
    University of Rochester Medical Center, Rochester, New York, USA
    Cancer Prev Res (Phila) 5:621-30. 2012
    ..Genistein displayed a possible bimodal effect (more effective at the lower dose) on bladder cancer tissue EGFR phosphorylation that should be evaluated further, possibly in combination with other agents...
  3. ncbi The Wisconsin Network for Health Research (WiNHR): a statewide, collaborative, multi-disciplinary, research group
    Howard Bailey
    University of Wisconsin School of Medicine and Public Health, Madison 53792, USA
    WMJ 108:453-8. 2009
    ..This optimism is based on the relevance of its goals to public health, the quality of statewide health care research, and, most importantly, the residents of Wisconsin who recognize the value of health research...
  4. ncbi Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy
    Sherry Morgan-Meadows
    University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA
    Invest New Drugs 20:377-82. 2002
    ..The objectives of this trial were to assess the maximal tolerated dose and toxicity of the combination of oral eniluracil and 5-fluorouracil and intravenous gemcitabine...
  5. ncbi Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer
    Sherry Morgan Meadows
    Department of Medicine, Division of Medical Oncology, The University of Wisconsin, Madison, WI, USA
    Int J Gastrointest Cancer 32:125-8. 2002
    ..This is a phase II study of perillyl alcohol in the treatment of patients with metastatic colorectal carcinoma. The primary endpoint is time to progression. Secondary objectives are to evaluate objective response rate and toxicity...
  6. ncbi Phase I trial of perillyl alcohol administered four times daily continuously
    Sherry Morgan-Meadows
    University of Wisconsin Comprehensive Cancer Center, 600 Highland Ave K4 601, Madison, Wisconsin 53792, USA
    Cancer Chemother Pharmacol 52:361-6. 2003
    ..Therefore, a new formulation of POH was developed (700 mg containing 675 mg POH) in an effort to improve dose and metabolite concentrations delivered and toxicity encountered with chronic dosing...
  7. ncbi A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma
    Sherry Morgan-Meadows
    University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792, USA
    Oncology 69:130-4. 2005
    ..The aim of this study was to evaluate the overall response rate, toxicity and overall survival in patients with locally advanced or metastatic esophageal cancer treated with gemcitabine, 5-fluorouracil (5-FU) and leucovorin...
  8. ncbi A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors
    William Schelman
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K4 530 CSC, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 62:727-33. 2008
    ..We conducted a phase I trial to assess the maximum tolerated dose, dose limiting toxicity (DLT) and antitumor activity of gemcitabine and patupilone...
  9. ncbi The differential diagnosis of pulmonary blastomycosis using case vignettes: a Wisconsin Network for Health Research (WiNHR) study
    Dennis J Baumgardner
    Department of Family Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee, USA
    WMJ 110:68-73. 2011
    ..This study addressed the diagnostic accuracy of physicians responding to case vignettes of pulmonary blastomycosis and the primary care differential diagnosis of this disease...